A study on etiological factors in splanchnic venous thrombosis using JAK-2 mutation

Dr. Prakash D Valse and Dr. Md. Akheeluddin Khaja

DOI: https://doi.org/10.33545/surgery.2021.v5.i1d.615

Abstract
Background: Splanchnic venous thrombosis is a rare disorder with multiple causes. The prevalence and cause of SVT vary in different parts of the world. Interaction between genetic and acquired risk factors is important in this disorder. Several conditions associated with hypercoagulability have been implicated in the causation of SVT.

Aim and Objective: To study etiological factors in splanchnic venous thrombosis using JAK-2 mutation

Methodology: This was a prospective study conducted in Department of Surgical Gastroenterology, Nizam’s Institute of Medical sciences, Hyderabad from January 2013 to June 2014. Diagnosed cases of Budd-Chairi syndrome (BCS), portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT) admitted or attended outpatient department were included. Eighty five patients were included in study group. They were divided in two sub groups. Group I constitute initial 60 cases those who underwent Protein C, Protein S, ATIII, Homocystien and APL antibody evaluation. About 65 percent of patients were found to have unknown aetiology. So increase the yield of diagnostic tests we added FVL mutation and JAK-2 V617F studies in next 25 cases on trail basis. Group II constitute of those 25 cases with mutational analysis.

Results: The mean age group (in years) in study was 32.57 (13-75) years. Deficiencies of protein C activity were observed in 9 (15%) patients with splanchnic venous thrombosis. Protein C deficiency was most common etiological factor noticed in our study 16.25% (13/85). Further in subgroup analysis it was more common in MVT group 20.68% (6/29) compared to BCS and PVT group 14.28 and 10.71%. Protein S deficiency was seen in 11.76% (10/85) cases in our study group. PVT group had shown more incidence 14.28% (4/28) followed by MVT 13.79% (4/29) and BCS 7.14% (2/28). Antithrombin III deficiency was observed in 3 (10.71%) of 28 cases of Budd Chaiir Syndrome, 2 (7.14%) of 28 cases of portal vein thrombosis and 2 (6.89%) of 29 cases of mesenteric vein thrombosis. After mutational analysis etiological factors were detected in 47.05% (40/85). Fifty three percent cases etiological factor was still not unknown.

Conclusion: Protein C is most common etiological factor in our study. Protein S was second most common etiological factor in study group. It has multifactorial aetiology can be the result of a combined effect of different pathogenesis mechanisms. Jack 2 mutations is not common in Indian Population.

Keywords: Protein C, protein S, antithrombin III, budd chairi syndrome, splanchnic venous thrombosis

Introduction
Abdominal vein thrombosis or splanchnic vein thrombosis is a rare, but life-threatening form of venous thrombosis and includes hepatic vein thrombosis Budd-Chiari syndrome, (BCS), portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT) [1]. BCS and PVT defined as primary if they are caused by a primarily venous disease, and defined as secondary if caused by compression or invasion by lesions originating outside the veins, such as benign or malignant tumors, abscesses, or cysts [2].

The annual incidence of BCS is 0.4 to 0.8 per million individuals in Western Countries [3, 4] and 0.1 per million in Japan [5]. BCS has a prevalence of 1.4 per million individuals in Western Countries [4] and 2.4 per million in Japan [3]. The annual incidence of superior mesenteric vein thrombosis is 2.7 per 100,000 individuals [5]. Isolated MVT without concomitant extra hepatic portal vein obstruction (EHPVO) and splenic vein thrombosis is rare [6]. MVT presentation can be acute, sub-acute, or chronic [7]. Acute thrombosis is associated with a bowel infarction in one-third of the patients and the mortality rate of MVT is 20% [4]. In most of the patients, the onset of MVT is characterized by acute abdominal pain. Other common symptoms include diarrhea, nausea, vomiting, and lower gastrointestinal bleeding [8]. MVT is associated with EHPVO in 65% of patients [9] and chronic presentation with no acute abdominal
pain and extensive venous collateral circulation is common [8]. In recent years several large-scale studies have been performed to study the underlying aetiological factors in these thrombotic disorders. Both inherited and acquired thrombophilia factors are frequently observed in these patients. Factor V Leiden mutation is frequently found in patients with BCS and prothrombin gene variant is seen more frequently in PVT. Myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia, are underlying disorders in 30–40% of patients with abdominal vein thrombosis. Other aetiological factors are paroxysmal nocturnal haemoglobinuria (PNH), autoimmune disorders and hormonal factors. Primary splanchic venous thrombosis is a multifactorial diseases as several prothrombotic disorders can be seen in same individual [10]. This justifies the need for a comprehensive thrombophilia screening in these subjects, even in the presence of known underlying predisposing factors or of obvious precipitating abdominal causes.

In the last decade the availability of advanced imaging procedures such as Doppler ultrasound, computer tomography (CT), and magnetic resonance imaging (MRI) allowed a better diagnosis of SVT in a large number of clinical settings ranging from fortuitous asymptomatic occlusions to acute abdomen. Moreover, the possibility of diagnosing SVT earlier results in a more prompt and effective therapy that translates in decreased morbidity and mortality [10]. SVT have been associated with various hypercoagulable states. Studies on etiopathologic factors for SVT are few, and most of them lack a complete workup for the prothrombotic state. To our knowledge, there is single study available on BCS and MVT from western India while other study was from northern India on BCS. There is no available data from southern India on etiological spectrum of SVT, so we conducted this study.

Objectives of the study
- To study etiological factors in splanchic venous thrombosis using JAK-2 mutation

Material and Methods
This was a prospective study conducted in Department of Surgical Gastroenterology, Nizam’s Institute of Medical sciences, Hyderabad from January 2013 to June 2014. Diagnosed cases of Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT) admitted or attended outpatient department were included. Refereed cases from the departments of Medical Gastroenterology and General medicine were also included in the study.

Inclusion criteria
Patients who were diagnosed with primary BCS, PVT and MVT including acute and chronic venous thrombosis, at any age group who attended inpatient or outpatient care were included.

Exclusion criteria
All patients with secondary causes of venous thrombosis were excluded from study like, pregnancy, oral contraceptive use, nephrotic syndrome, hormone replacement syndrome, Local factors (omphalitis, pancreatitis, diverticulitis, cholecystitis) Portal vein axis injury (splenectomy, cholecystectomy, colectomy).

Diagnosis
Mesenteric venous thrombosis is diagnosed on the basis of US puled-Doppler and CECT Abdomen [10]. PVT was diagnosed in the presence of endoluminal material and absence of flow in the portal vein, or cavernous transformation of the vein as shown by duplex-Doppler ultrasound, or contrast enhanced CT scan or magnetic resonance imaging HVT was diagnosed according to previously published criteria i.e. small hepatic veins (HV), large HVs, inferior vena cava (IVC), and combined obstruction of large HVs and IVC.

Blood sample collection
In patients presenting with acute thrombosis, samples were collected before starting conventional IV heparin. Patients who were already on oral anticoagulants are advised to withhold medication for two weeks and switch over to low molecular weight heparin 2500 international units subcutaneously once daily. Blood sample had been collected about 10 ml. Complete blood picture, renal function test, liver function test, Prothrombin time checked along with work for thrombophilia- protein C, protein S, homocysteine, antithrombin III, anti-phospholipid antibody, prothrombin gene mutation, factor V Leiden mutation, JAK-2 mutation.

Patients were advised to undergo Upper GI endoscopy for to look for varices.

Eighty five patients were included in study group. They were divided in two sub groups. Group I constitute initial 60 cases those who underwent Protein C, Protein S, ATIII, Homocystein and APL antibody evaluation. About 65 percent of patients were found to have unknown aetiology. So increase the yield of diagnostic tests we added FVL mutation and JAK-2 V617F studies in next 25 cases on trail basis. Group II constitute of those 25 cases with mutational analysis.

Protein C
Protein C was tested by Photo-optical clot detection method. The patient sample is incubated with and without exogenous activated protein C (APC). Activated factor V (FVa) is broken down by APC, reducing conversion of prothrombin to thrombin and extending the clotting time. If factor V mutation is present, FVa breakdown is inhibited, leading to a shorter clotting time. Results are expressed as the ratio of clotting times obtained with and without exogenous APC.

Protein S
Clot detection method. Protein S in the patient sample enhances the anticoagulant action of activated protein C, resulting in a prolonged clotting time. The increase in clotting time is directly proportional to the percent of normal protein S activity.

Antithrombin III
ATIII activity was tested by chromogenic method. Antithrombin in the patients sample binds to thrombin; excess thrombin cleaves a synthetic thrombin substrate, the amount of which is inversely proportional to the amount of antithrombin activity in the plasma.

Homocysteine
Homocysteine was detected by Competitive immunoassay method. The level of total homocysteine (i.e. protein-bound, oxidized, and free, reduced homocysteine) is measured in a competitive immune chemilumimetric assay.

Antiphospholipid antibody
APL ab was detected by ELISA test. The level of antibodies
directed against various plasma proteins that bind to phospholipid surfaces (eg, damaged endothelial membranes, monocytes, tumor cells, etc) is measured. The method is highly sensitive but not specific for \( \beta \)2-glycoprotein I antibodies. Individual tests for IgA, IgG, and IgM antibodies are available.

**Factor V Leiden mutation analysis**

FVLm was done by PCR assay. It detects oligonucleotide ligation, fluorescent detection. The 1691G>A factor V Leiden mutation is determined by amplification of the gene region with PCR, followed by oligonucleotide ligation and hybridization to colour-coded microspheres. Results are reported as no mutation detected, heterozygous positive, or homozygous positive.

**JAK-2 V-617F**

JAK-2 V617 F was detected by Reverse transcription PCR, sequencing. PCR and sequencing are performed as described above to detect the V617F mutation; if negative, an additional PCR and sequencing will be performed to detect JAK2 mutations in exons 12 and 13.

**Ethics committee**

The Study was approved by institutional ethics committee, reviews letter no EC/NIMS/1411/2013, 7th ECGS NO: 103/13. Informed consent was taken from all patients included in study.

**Statistical analysis**

Statistical analysis was performed using SPSS 17 software. Categorical variables were compared by Chi-square test when applicable. Continuous variables were analyzed by student t test or Mann Whitney U test when applicable. Continuous data was expressed as mean ± standard error of mean.

**Results**

Eighty five patients with splanchnic venous thrombosis (SVT) were evaluated for etiological workup during study period (January 2013-June 2014) in our Department of Surgical Gastroenterology and Department of Medical Gastroenterology Nizam’s Institute Of Medical Sciences Hyderabad.

**Division of patients according to diagnosis**

These eighty five patients were divided as per site of thrombosis in three groups:

1. Budd Chari Syndrome (BCS) n-28
2. Portal Vein Thrombosis (PVT) n-28
3. Mesenteric Venous Thrombosis n-29.

**Table 1: Division of patients according to diagnosis**

| Diagnosis                        | Number of patients | %   |
|----------------------------------|--------------------|-----|
| Budd-Chari Syndrome              | 28                 | 32.9|
| Portal vein thrombosis           | 29                 | 34.5|
| Mesenteric venous thrombosis     | 28                 | 32.9|

**Age at presentation**

The mean age group (in years) in study was 32.57(13-75) years. The youngest patient was 13 years and the oldest was 75 years. About 50 percentiles of patients were below 30 years of age group as shown in table no.2.

**Table 2: Showing patient percentiles with age group**

| Percentiles | Age |
|-------------|-----|
| 25          | 22.5|
| 50          | 30  |
| 75          | 40  |

**Gender distribution**

There were 45 male patients and 40 female patients (M: F: 1.12: 1). Of 28 patients with BCS, 9 (32%) were male, and 19 (67%) were female; 13 (46.42%) of 28 patients with PVT were male and 23 (79.3%) of 29 patients who suffered MVT were male. There was no statically deference found when compared gender distribution in inherited thrombophilic factors.

**Table 3: Gender characteristics studied in BCS, PVT and MVT**

| Gender | Study n (%) | BCS n (%) | PVT n (%) | MVT n (%) |
|--------|-------------|-----------|-----------|-----------|
| Male   | 45 (52)     | 9 (32.14) | 13 (46.42)| 23 (79.31) |
| Female | 40 (48)     | 19 (67.85)| 15 (53.58)| 6 (20.79)  |

**Table 4: Gender distribution of patients studied under various inherited thrombophilic factors**

| Test/Sex               | Female n (%) | Male n (%) | p value (†) |
|------------------------|--------------|------------|-------------|
| Protein C deficiency   | Absent       | 34(85)     | 38(84.4)    | 0.569       |
|                        | Present      | 6(15)      | 7(15.6)     |             |
| Protein S deficiency   | Absent       | 37(92.5)   | 38(84.4)    | 0.65        |
|                        | Present      | 3(7.5)     | 7(15.6)     |             |
| Hyperhomocystinemia    | Absent       | 36(90)     | 40(88.9)    | 0.337       |
|                        | Present      | 4(10)      | 5(11.1)     |             |
| AT III Deficiency      | Absent       | 37(92.5)   | 41(91.1)    | 0.843       |
|                        | Present      | 3(7.5)     | 4(8.9)      |             |
| APL Ab                 | Absent       | 19(47.5)   | 28(62.2)    | 0.219       |
|                        | Present      | 2(5)       | 1(2.2)      |             |
| FVLM                   | Absent       | 10(25)     | 15(33.3)    | 0.21        |
|                        | Present      | 0(0)       | 0(0)        |             |
| JAK2V617 Mutation      | Absent       | 9(22.5)    | 15(33.3)    | 0.207       |
|                        | Present      | 1(2.5)     | 0(0)        |             |

Numbers in parenthesis are row percentages; † indicate Pearson Chi-square test.

The above table clearly shows that there are no significant difference between males and females suffering from various inherited thrombophilic factors. Protein C Deficiency was revealed in 6(46%) females and 7(54%) males. 70% of males suffered from Protein S Deficiency. Two females of 3 individuals had circulating Anti Phospholipid Ab.

Eighty five patients were included in study group. They were divided in two sub groups. Group I constitute initial 60 cases those who underwent Protein C, Protein S, ATIII, Homocystein and APL antibody evaluation. About 65 percent of patients were found to have unknown aetiology. So increase the yield of diagnostic tests we added FVL mutation and JAK-2 V617F.
studies in next 25 cases on trial basis. Group II constitute of those 25 cases with mutational analysis. Deficiencies of protein C activity were observed in 9 (15%) patients with splanchnic venous thrombosis. Six (10%) of 60 patients of splanchnic vein thrombosis had Protein S deficiency. None of the 21 patients of Budd Chiari Syndrome had Protein S deficiency. Elevated homocysteine levels were associated with 5(8.33%) of 60 patients of splanchnic vein thrombosis, only 1 (4.76%) of 21 patients of Budd-Chairi Syndrome had hyperhomocysteinemia. Antithrombin III deficiency was observed in 1 (4.76%) of 21 cases of Budd Chairi Syndrome, 2 (9.09%) of 22 cases of portal vein thrombosis and 3(17.64%) of 17 cases of mesenteric vein thrombosis, thus comprising of 6(10%) subjects of 60 cases of splanchnic vein thrombosis with antithrombin III deficiency. Antiphospholipid antibody was observed in 1(4.76%) of 21 cases of Budd Chairi Syndrome and 1(5.88%) of 22 cases of mesenteric vein thrombosis, thus comprising of 2(3.33%) subjects of 60 cases of splanchnic vein thrombosis with Antiphospholipid antibody. Multifactorial aetiology was found in 7(11.66%) cases. Definite etiological factor was found in 20(33.33%) cases.

Group I

Table 6(A and B): Differences in prevalence of protein C deficiency, protein S deficiency, antithrombin deficiency homocysteine and APL-ab in 60 patients with Budd-Chiari syndrome (BCS), PVT and MVT

Table 6A

| Test                        | Study group (n=60) |
|-----------------------------|-------------------|
| Protein C deficiency        | 9 (15)            |
| Protein S deficiency        | 6 (10)            |
| ATIII deficiency            | 6 (10)            |
| Hyper homocysteinemia       | 5 (8.33)          |
| APL-ab                      | 2 (3.33)          |
| Multifactorial              | 7 (11.66)         |

Table 6B

| Test                        | Study group (n=21) | PVT (n=22) | MVT (n=17) |
|-----------------------------|-------------------|------------|------------|
| Protein C deficiency        | 3 (14.2)          | 3 (13.63)  | 3 (17.64)  |
| Protein S deficiency        | 0                 | 2 (9.09)   | 4 (23.52)  |
| ATIII deficiency            | 1 (4.76)          | 2 (9.09)   | 3 (17.64)  |
| Hyperhomocysteinemia        | 1 (4.76)          | 2 (9.09)   | 3 (17.64)  |
| APL-ab                      | 1 (4.76)          | 0          | 5 (8.88)   |
| Multifactorial              | 2 (9.52)          | 2 (9.09)   | 3 (17.64)  |

Group II

In this group two genetic mutational factors (JAK-2V617F, FVLM) were added in above battery of tests. This test was done on trail basis in latter 25 cases.

Table 7(A and B): Differences in prevalence of protein C deficiency, protein S deficiency, antithrombin deficiency, hyperhomocysteinemia.

| Test                        | Study group (n=25) |
|-----------------------------|-------------------|
| Protein C deficiency        | 4 (16)            |
| Protein S deficiency        | 4 (16)            |
| ATIII deficiency            | 1 (4)             |
| Hyperhomocysteinemia        | 4 (16)            |
| APL Ab                      | 1 (5.2)           |
| FVLM                        | -                 |
| JAK-2V617                   | 1 (4)             |
| Multifactorial              | 3 (12)            |

Table 7B

| Test                        | BCS (n=7) | PVT (n=6) | MVT (n=12) |
|-----------------------------|-----------|-----------|------------|
| Protein C deficiency        | 1 (14.2)  | -         | 3 (25)     |
| Protein S deficiency        | 1 (14.2)  | 3 (50)    | -          |
| ATIII deficiency            | 1 (14.2)  | -         | -          |
| Hyperhomocysteinemia        | -         | 3 (50)    | 1 (8.3)    |
| APL Ab                      | -         | 1 (25)    | -          |
| FVLM                        | -         | -         | -          |
| JAK-2V617                   | -         | 1 (16.6)  | -          |
| Multifactorial              | 1 (14.2)  | 2 (33.3)  | -          |

Of 25 patients investigated later, there were 4(16%) patients each with protein C deficiency, protein S deficiency and homocysteinaemia; 3(12%) of 25 cases had multifactorial incidence. Single patient in PVT group detected positive for JAK-2V617F. None of our patient in this group was detected for FVLM. In this group we could detect definite etiological factor in 52% (13/25) cases.

Table 8: Differences in prevalence of protein C deficiency, protein S deficiency, antithrombin deficiency, homocysteine and APL-ab, JAK-2 Mutation and FVLM in study group

Table 8A

| Test                        | Study group (n=85) |
|-----------------------------|-------------------|
| Protein C Deficiency        | 13 (15.29)        |
| Protein S Deficiency        | 10 (11.36)        |
| ATIII Deficiency            | 7 (8.23)          |
| Hyperhomocysteinemia        | 9 (10.58)         |
| APL-Ab*                     | 3 (6.0)           |

Table 8B

| Diagnosis                  | BCS n (%) | PVT n (%) | MVT n (%) | p Value  |
|---------------------------|-----------|-----------|-----------|----------|
| Protein C Deficiency      | Absent    | 24 (85.7) | 25 (89.3) | 23 (79.3) | 0.569    |
| Present                   | 4 (14.3)  | 3 (10.7)  | 6 (20.7)  |          |          |
| Protein S Deficiency      | Absent    | 26 (92.9) | 24 (85.7) | 25 (86.2) | 0.65     |
| Present                   | 2 (7.1)   | 4 (14.3)  | 4 (13.8)  |          |          |
| Hyperhomocysteinemia      | Absent    | 27 (96.4) | 24 (85.7) | 25 (86.2) | 0.337    |
| Present                   | 1 (3.6)   | 4 (14.3)  | 4 (13.8)  |          |          |
| AT III Deficiency         | Absent    | 25 (89.3) | 26 (92.9) | 27 (93.1) | 0.843    |
| Present                   | 3 (10.7)  | 2 (7.1)   | 2 (6.9)   |          |          |
| FVLM                      | Absent    | 7 (25)    | 6 (21.4)  | 12 (41.4) | 0.21     |
| JAK2V617                  | Absent    | 7 (25)    | 5 (17.9)  | 12 (41.4) | 0.207    |
| Positive                  | 0 (0)     | 1 (3.6)   | 0 (0)     |          |          |
| APL-Ab                    | Absent    | 12 (42.90)| 14 (50)   | 21 (72.4) | 0.219    |
| Positive                  | 1 (3.6)   | 1 (3.6)   | 1 (3.4)   |          |          |

Numbers in parenthesis are row percentages
Deficiencies of protein C activity were observed in 13(15.29%) patients of splanchic venous thrombosis. Ten (11.76%) of 85 patients of splanchic vein thrombosis had Protein S deficiency. Only 2(7.14%) of 28 patients of Budd Chiari Syndrome had Protein S deficiency. Elevated homocysteine levels were associated with 9 (10.58%) of 85 patients of splanchic vein thrombosis, only 1 (3.57%) of 28 patients of Budd-Chiari Syndrome had hyperhomocysteineemia. Antithrombin III deficiency was observed in 2(7.14%) of 28 cases of Budd Chiari Syndrome, 2 (7.14%) of 28 cases of portal vein thrombosis and 3(10.34%) of 29 cases of mesenteric vein thrombosis, thus comprising of 7 (8.23%) subjects of 85 cases of splanchic vein thrombosis with antithrombin III deficiency. Antiphospholipid antibody was observed in 1 (7.69%) of 13 cases of Budd Chiari Syndrome, 1 (6.66%) of 15 cases of portal vein thrombosis and 1 (4.45%) of 22 cases of mesenteric vein thrombosis, thus comprising of 3(6%) subjects of 50 cases of splanchic vein thrombosis with Antiphospholipid antibody.

Multifactorial aetiology in SVT
Multifactorial aetiology was found in 11.76% (10/85) cases. Four (4.70%) cases had combined Protein C and S deficiency. Single patient in six various combinations were found in study group. Multifactorial aetiology was found in 11.76 % (10/85) cases. Five (5.88%) cases had combined Protein C and S deficiency. Two (2.35%) cases had Protein C and ATIII deficiency. One patient with hyperhomocysteinemla had Protein C deficiency and other one had Protein S deficiency. Protein C, Protein S and ATIII deficiency was noticed in one patient.

Table 9: Number and percentage of patients having multifactorial etiology in SVT

| Multifactorial etiology in SVT | n (%) |
|-------------------------------|-------|
| Protein C and Protein S deficiency | 4 (4.70) |
| Protein C and ATIII deficiency | 1 (1.17) |
| Protein S deficiency and Hyperhomocysteinemla | 1 (1.17) |
| Anti-phospholipid antibody and ATIII deficiency | 1 (1.17) |
| Protein C, Protein S deficiency and Hyperhomocysteinemla | 1 (1.17) |
| Anti-phospholipid antibody and Hyper-homocysteinemla | 1 (1.17) |
| JAK-2 V617F mutation and Hyperhomocysteinemla | 1 (1.17) |
| Total | 10 (11.76) |

Discussion
Splanchnic venous thrombosis is a rare disorder with multiple causes. The prevalence and cause of SVT vary in different parts of the world. Interaction between genetic and acquired risk factors is important in this disorder. Several conditions associated with hypercoagulability have been implicated in the causation of SVT. Our study includes all three forms of splanchnic venous thrombosis i.e. BCS, PVT, MVT. This is unique feature of our study.

Almost 69% of cases were aged <40 years; hypercoagulable state was identified in 49.35%. The age of presentation ranges from 13 to 75 years, with mean age of patients 32.57 years and male to female ratio is 1.12: 1. Of 28 patients with BCS, 19 (67%) were female; 15 (53.57%) of 28 patients with PVT were female and 23 (79.3%) of 29 patients who suffered MVT were male.

Cond at et al. [13] had study population with equal gender distribution (M/F=77/64) M: F was 1.2 and mean age group 44 years. Janssen et al. had study population with mean age 40 yrs in BCS group and 51yrs in PVT group. Sex ratio in this study was M: F (1:2.2) M/F (16 /37) in BCS group and M: F (1:1.08) M/F (48 /52) in PVT group.

The prevalence of primary deficiencies in Protein C, Protein S, and Antithrombin III in BCS patients is difficult to determine, for several reasons. Firstly, the liver synthesizes these inhibitors of coagulation, and liver dysfunction related to BCS thus induces non-specific falls in the plasma levels of the inhibitors. Secondly, diagnosis of any primary deficiency is based on measurement of plasma protein level, because most mutations in the relevant genes are unique, rendering diagnosis using molecular biology techniques alone difficult. Finally, complete family screening is recommended to differentiate between inherited and false instances of deficiencies in Proteins C and S, but this is usually impractical. In all of our patients with protein C and protein S deficiencies, an acquired deficiency was ruled out by normal liver function test results and a normal prothrombin time. None of our patients were receiving anticoagulant therapy at the time of protein C and protein S estimation.

Protein C deficiency
Protein C deficiency was most common etiological factor noticed in our study 16.25% (13/85).Further in subgroup analysis it was more common in MVT group20.68%(6/29) compared to BCS and PVT group 14.28 and 10.71%.

Protein C deficiency was found to have etiological factor in 1-9% cases of PVT and BCS in previously published studies [11, 12]. Janssen et al. [10] showed Protein C deficiency was seen 7.6% and 9.3% in PVT and BCS respectively. Condat et al. [13] noticed 3% cases of Protein C deficiency. Egesel T et al. [14] shown Protein C deficiency in 26% cases of PVT. Denninger et al. [15] and Primignani et al. [16] could not found single case with protein C deficiency in PVT group.

Protein S deficiency
Protein S deficiency was seen in 11.76% (10/85) cases in our study group. PVT group had shown more incidence 14.28% (4/28) followed by MVT 13.79% (4/29) and BCS 7.14% (2/28).

Protein S deficiency was seen in 2.3% in PVT group. While Bhattacharya et al. [17] noticed Protein S deficiency 4% of PVT cases and 12% of BCS cases. B. Condat et al. [13] noticed 9% cases of Protein S deficiency. Egesel T et al. [14] had shown Protein S deficiency in 43% cases of PVT. Denninger et al. [15] and Primignani et al. [16] was noticed protein C deficiency in 30% and 2% cases PVT group respectively.

Antithrombin III deficiency
Antithrombin III deficiency was observed in 3 (10.71%) of 28 cases of Budd Chiari Syndrome, 2 (7.14%) of 28 cases of portal vein thrombosis and 2 (6.89%) of 29 cases of mesenteric vein thrombosis, thus comprising of 7 (8.23%) subjects of 85 cases of splanchnic vein thrombosis with antithrombin III deficiency in our study.

A-III deficiency was found to have etiological factor in 2-5% cases of abdominal vein thrombosis in previously published studies [11, 12]. Janssen et al. (2000) [10] showed AT-III deficiency was seen 1% in PVT group. B. Condat et al. noticed 9% cases of AT-III deficiency. Egesel T et al. [14] had shown AT-III deficiency in 26% cases of PVT. Denninger et al. [15] and Primignani et al. [16] was noticed AT-III deficiency in 4% and 5% cases PVT group respectively. Studies conducted by Mohanty et al. [18] and Uskudar et al. [19], while working on patients with BCS showed...
antithrombin III deficiency in 4.3%, 3.8% and 3%.

**Hyperhomocysteinemia**

Elevated homocysteine levels were associated with 9 (10.85%) of 85 patients of splanchnic vein thrombosis, only 1 (3.57%) of 28 patients of Budd-Chiari Syndrome had hyperhomocysteinemia. Previous studies were shown 2-19% incidence of Hyperhomocysteinemia in their cohort [11]. Primignani et al. had shown Hyperhomocysteinemia in 12% cases of PVT [20].

**Antiphospholipid antibody**

Antiphospholipid antibody test was done in only 50/85 cases. Three (3/50) patients were detected to have antiphospholipid antibody. In each group one patient was detected antiphospholipid antibody. In PVT group antiphospholipid antibody was detected in 6.66 % (1/15) cases. In BCS group antiphospholipid antibody was detected in 7.66 % (1/13) cases. In MVT group antiphospholipid antibody was detected in 4.45 % (1/22) cases.

Previous studies were shown antiphospholipid antibody was detected up to 20% cases of BCS and 10% cases of PVT. Mohanty et al. [18] had shown APL-ab was detected in 11.3% cases in BCS. Primignani et al. had shown APL-ab in 6 % cases of PVT [16].

**Genetic mutational studies**

After completing above mentioned tests, etiological factors were detected in 45.88% (39/85) cases in study group. Still 55% cases etiology was unknown, so last 26 (BCS 8, PVT 6 and MVT 12) cases were subjected for genetic mutational analysis i.e. Factor V Leiden mutation and JAK-2 V617 mutation.

JAK-V617F was detected in single 3.86% (1/26) patient in PVT group. This case was a middle aged lady, presented with pain abdomen detected to have PVT on USG abdomen followed by Doppler scan. She doesn’t have any features of myeloproliferative disorder on hematological or radiological investigations, so detected to have occult MPD. MPNs are observed in 30-40% of patients with BCS or PVT, whereas this is rarely the cause of other types of VTE [21, 22]. While Mahmoud AE et al. had shown 23% cases with factor V Leiden positivity and 6.6% cases in PVT [18]. Mohanty et al. had shown FVLM was detected in 26.4% cases in BCS. Primignani et al. had shown FVLM in 23% cases of PVT [16]. After mutational analysis etiological factors were detected in 47.05% (40/85). Fifty three percent cases etiological factor was still not unknown.

**Multifactorial etiology**

Multifactorial etiology was noticed in 11.76 % (10/85) cases in our study. Various studies shown that multifactorial etiology seen in 10-50% cases. Although these studies considered primary as well as secondary etiological factors. Janssen et al. [10] had observed occurrence of either acquired or inherited thrombotic risk factors in 26% of the BCS patients and 37% of the PVT patients. Mohanty et al. [18] had observed multifactorial etiology in 11.32% cases of BCS.

**Conclusion**

- Protein C is most common etiological factor in our study.
- Protein S was second most common etiological factor in study group.
- JAK-2 mutational study is not common in Indian population
- About 40% cases of Primary SVT are still idiopathic.

- Primary Splanchnic Venous thrombosis is disease of young age.
- It has equal gender distribution.
- It has multifactorial aetiology can be the result of a combined effect of different pathogenesis mechanisms.

**Acknowledgment**

The author thankful to Department of General Surgery for providing all the facilities to carry out this work.

**Conflict of interest**

None

**Financial support**

Nil

**References**

1. Plessier A, Darwish Murad S, Hernandez Guerra M et al. European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2009;51:210-8.
2. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. European Group for the Study of Vascular Disorders of the Liver. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
3. Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004;19:S204-S211.
4. Rajani R, Melin T, Björnsson E, Broome Ü, Sangfelt P, Danielsson A et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int 2009;29:253-9.
5. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis, Br J Surg 2008;95:1245-51.
6. Dentali F, Ageno W, Witt D, Malato A, Clark N, Garcia D et al. WARPED consortium. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost 2009, P102.
7. Denninger MH, Chait Y, Casadevall N et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000;31:587-591.
8. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001;345:1683-8.
9. Acosta S, Ogren M, Sternby NH, Bergqvist D, Björck M. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. J Vasc Surg 2005;41:59-63.
10. Janssen HL, Meindari JR, Vleggaar FP et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a casecontrol study. Blood 2000;96:2364-2368.
11. Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001;49:720-4.
12. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997;23:411-8.
13. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466-70.

14. Egesel T, Buyukasik Y, Dundar SV et al. The role of natural anticoagulant deficiencies and Factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000;30:66-71.

15. Denninger MH, Helley D, Valla D et al. Prospective evaluation of the prevalence of Factor V Leiden mutation in portal or hepatic vein thrombosis. Thromb Haemost 1997;78:1297-1298.

16. Primignani M, Martinelli I, Bucciarelli P et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603-608.

17. Maitreyee Bhattacharyya, Govind Makharia M, Kannan RPH, Ahmed Gupta PK, Renu Saxena. Inherited Prothrombotic Defects in Budd-Chiari Syndrome and Portal Vein Thrombosis A Study From North India: Am J Clin Pathol 2004;121:844-847.

18. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001;34:666-670.

19. Uskudar O, Akdogan M, Sasmaz N, Yilmaz S, Tola M, Sahin B. Etiology and portal vein thrombosis in Budd-Chiari syndrome. World J Gastroenterology 2008;14:2858-2862.

20. McClure S, Dincsoy HP, Glueck H. Budd-Chiari syndrome and antithrombin III deficiency. Am J Clin Pathol 1982;78:236-241.

21. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008;22:2020-8.

22. Hoekstra J, Leebeek FW, Plessier A et al. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 2009;51:696-706.